Duration and Dose of Adjuvant Zoledronic Acid for Treatment of Early Breast Cancer-Reply

Affiliations

Comment

Thomas W P Friedl et al. JAMA Oncol. 2022.

. 2022 Jan 1;8(1):171-172.

doi: 10.1001/jamaoncol.2021.5768.

¹ Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.

No abstract available

Comment on

Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial.
Friedl TWP, Fehm T, Müller V, Lichtenegger W, Blohmer J, Lorenz R, Forstbauer H, Fink V, Bekes I, Huober J, Jückstock J, Schneeweiss A, Tesch H, Mahner S, Brucker SY, Heinrich G, Häberle L, Fasching PA, Beckmann MW, Coleman RE, Janni W, Rack B. Friedl TWP, et al. JAMA Oncol. 2021 Aug 1;7(8):1149-1157. doi: 10.1001/jamaoncol.2021.1854. JAMA Oncol. 2021. PMID: 34165508 Free PMC article. Clinical Trial.
Duration and Dose of Adjuvant Zoledronic Acid for Treatment of Early Breast Cancer.
Sorscher S. Sorscher S. JAMA Oncol. 2022 Jan 1;8(1):171. doi: 10.1001/jamaoncol.2021.5765. JAMA Oncol. 2022. PMID: 34792535 No abstract available.